Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $126,719.91 in Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson sold 7,779 shares of the stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $16.29, for a total transaction of $126,719.91. Following the completion of the sale, the director now directly owns 447,857 shares of the company’s stock, valued at $7,295,590.53. This trade represents a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Tyra Biosciences Price Performance

NASDAQ:TYRA traded down $0.28 during trading hours on Tuesday, reaching $15.91. The company’s stock had a trading volume of 187,035 shares, compared to its average volume of 297,086. The company has a market cap of $805.05 million, a price-to-earnings ratio of -9.88 and a beta of 1.04. Tyra Biosciences, Inc. has a one year low of $12.34 and a one year high of $29.60. The business’s 50-day moving average is $15.38 and its 200-day moving average is $19.20.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.01). On average, sell-side analysts predict that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Hedge Funds Weigh In On Tyra Biosciences

A number of institutional investors have recently made changes to their positions in TYRA. HighVista Strategies LLC bought a new stake in Tyra Biosciences during the 2nd quarter valued at approximately $257,000. Franklin Resources Inc. bought a new position in shares of Tyra Biosciences during the 3rd quarter worth about $278,000. Valence8 US LP bought a new position in shares of Tyra Biosciences during the 3rd quarter worth about $310,000. SG Americas Securities LLC acquired a new position in shares of Tyra Biosciences during the third quarter valued at about $311,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Tyra Biosciences in the third quarter valued at about $333,000. 84.14% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have issued reports on TYRA. UBS Group started coverage on shares of Tyra Biosciences in a research report on Tuesday, January 7th. They issued a “buy” rating and a $28.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Tyra Biosciences in a report on Monday, January 13th. Bank of America upgraded Tyra Biosciences from a “neutral” rating to a “buy” rating and boosted their target price for the company from $22.00 to $31.00 in a research note on Friday, October 18th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $28.00 target price on shares of Tyra Biosciences in a research report on Friday, October 25th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $30.50.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.